The future of immune checkpoint therapy

P Sharma, JP Allison - Science, 2015 - science.org
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance
antitumor immune responses, has led to important clinical advances and provided a new …

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

A Naimi, RN Mohammed, A Raji, S Chupradit… - Cell communication and …, 2022 - Springer
The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

HY Zheng, M Zhang, CX Yang, N Zhang… - Cellular & molecular …, 2020 - nature.com
The novel contagious primary atypical pneumonia epidemic, which broke out in Wuhan,
China, in December 2019, is now formally called Coronavirus Disease 2019 (COVID-19) …

Engineering strategies to enhance oncolytic viruses in cancer immunotherapy

Y Tian, D **e, L Yang - Signal transduction and targeted therapy, 2022 - nature.com
Oncolytic viruses (OVs) are emerging as potentially useful platforms in treatment methods for
patients with tumors. They preferentially target and kill tumor cells, leaving healthy cells …

Optimizing oncolytic virotherapy in cancer treatment

K Harrington, DJ Freeman, B Kelly, J Harper… - Nature reviews Drug …, 2019 - nature.com
In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

S Vafaei, AO Zekiy, RA Khanamir, BA Zaman… - Cancer Cell …, 2022 - Springer
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic
strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects …

Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma

PF Ferrucci, L Pala, F Conforti, E Cocorocchio - Cancers, 2021 - mdpi.com
Simple Summary Talimogene laherparepvec (T-VEC; IMLYGIC®, Amgen Inc.) is the first
oncolytic viral immunotherapy to be approved for the local treatment of unresectable …

[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway

C Ghosh, G Luong, Y Sun - Journal of Cancer, 2021 - ncbi.nlm.nih.gov
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …

Immunological landscape and immunotherapy of hepatocellular carcinoma

J Prieto, I Melero, B Sangro - Nature reviews Gastroenterology & …, 2015 - nature.com
Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …

Oncolytic viruses as engineering platforms for combination immunotherapy

K Twumasi-Boateng, JL Pettigrew, YYE Kwok… - Nature Reviews …, 2018 - nature.com
To effectively build on the recent successes of immune checkpoint blockade, adoptive T cell
therapy and cancer vaccines, it is critical to rationally design combination strategies that will …